[go: up one dir, main page]

WO2009001545A1 - 移植片対宿主疾患の検査および治療方法 - Google Patents

移植片対宿主疾患の検査および治療方法 Download PDF

Info

Publication number
WO2009001545A1
WO2009001545A1 PCT/JP2008/001625 JP2008001625W WO2009001545A1 WO 2009001545 A1 WO2009001545 A1 WO 2009001545A1 JP 2008001625 W JP2008001625 W JP 2008001625W WO 2009001545 A1 WO2009001545 A1 WO 2009001545A1
Authority
WO
WIPO (PCT)
Prior art keywords
versus host
graft versus
host disease
detection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001625
Other languages
English (en)
French (fr)
Inventor
Tsukasa Hori
Yasuo Kokai
Yasuyoshi Naishiro
Hiroyuki Tsutsumi
Kohzoh Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuno Biological Laboratories Co Ltd
Sapporo Medical University
Original Assignee
Immuno Biological Laboratories Co Ltd
Sapporo Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2692332A priority Critical patent/CA2692332C/en
Priority to CN200880021422.XA priority patent/CN101743473B/zh
Priority to RU2010101909/15A priority patent/RU2479846C2/ru
Priority to EP08764208.8A priority patent/EP2163896B1/en
Priority to US12/666,209 priority patent/US20100183586A1/en
Priority to AU2008268842A priority patent/AU2008268842B2/en
Application filed by Immuno Biological Laboratories Co Ltd, Sapporo Medical University filed Critical Immuno Biological Laboratories Co Ltd
Priority to KR1020107001343A priority patent/KR101432191B1/ko
Priority to JP2009520345A priority patent/JP5403752B2/ja
Publication of WO2009001545A1 publication Critical patent/WO2009001545A1/ja
Anticipated expiration legal-status Critical
Priority to US13/523,791 priority patent/US20130267430A2/en
Priority to US14/244,166 priority patent/US9631014B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

　被験者から得た試料中のＣＣＬ８蛋白質の量を測定し，得られた測定値を移植片対宿主疾患の診断または経過の指標とすることを特徴とする，移植片対宿主疾患を検査するための方法が開示される。また，抗ＣＣＬ８抗体を含む移植片対宿主疾患の検査薬も開示される。本発明の方法により，移植片対宿主疾患の発症の診断および経過のモニタリング，特に感染症との鑑別診断が可能である。さらに，抗ＣＣＬ８抗体を用いる移植片対宿主疾患の治療方法も提供される。
PCT/JP2008/001625 2007-06-22 2008-06-23 移植片対宿主疾患の検査および治療方法 Ceased WO2009001545A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020107001343A KR101432191B1 (ko) 2007-06-22 2008-06-23 이식편대숙주 질환의 검출 또는 치료 방법
CN200880021422.XA CN101743473B (zh) 2007-06-22 2008-06-23 移植物抗宿主疾病的检查及治疗方法
RU2010101909/15A RU2479846C2 (ru) 2007-06-22 2008-06-23 Способ выявления или лечения реакции "трансплантат против хозяина"
EP08764208.8A EP2163896B1 (en) 2007-06-22 2008-06-23 Method for detection or treatment of graft versus host disease
US12/666,209 US20100183586A1 (en) 2007-06-22 2008-06-23 Method for detection or treatment of graft versus host disease
CA2692332A CA2692332C (en) 2007-06-22 2008-06-23 Method for detection or treatment of graft versus host disease
JP2009520345A JP5403752B2 (ja) 2007-06-22 2008-06-23 移植片対宿主疾患の検査および治療方法
AU2008268842A AU2008268842B2 (en) 2007-06-22 2008-06-23 Method for detection or treatment of graft versus host disease
US13/523,791 US20130267430A2 (en) 2007-06-22 2012-06-14 Method and reagent for diagnosis and/or evaluation of progression of graft-versus-host disease
US14/244,166 US9631014B2 (en) 2007-06-22 2014-04-03 Method and reagent for diagnosis and/or evaluation of progression of graft-versus-host disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007165547 2007-06-22
JP2007-165547 2007-06-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/666,209 A-371-Of-International US20100183586A1 (en) 2007-06-22 2008-06-23 Method for detection or treatment of graft versus host disease
US13/523,791 Continuation US20130267430A2 (en) 2007-06-22 2012-06-14 Method and reagent for diagnosis and/or evaluation of progression of graft-versus-host disease

Publications (1)

Publication Number Publication Date
WO2009001545A1 true WO2009001545A1 (ja) 2008-12-31

Family

ID=40185370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001625 Ceased WO2009001545A1 (ja) 2007-06-22 2008-06-23 移植片対宿主疾患の検査および治療方法

Country Status (8)

Country Link
US (3) US20100183586A1 (ja)
EP (1) EP2163896B1 (ja)
JP (1) JP5403752B2 (ja)
KR (1) KR101432191B1 (ja)
CN (1) CN101743473B (ja)
CA (1) CA2692332C (ja)
RU (2) RU2479846C2 (ja)
WO (1) WO2009001545A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011024458A1 (ja) * 2009-08-26 2011-03-03 北海道公立大学法人 札幌医科大学 宿主対移植片疾患の検査方法
JP2016501526A (ja) * 2012-12-06 2016-01-21 エンリヴェックス セラピューティクス リミテッド 治療用アポトーシス細胞調製物、その製造方法及びその使用
RU2603461C1 (ru) * 2015-11-27 2016-11-27 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ подбора режима иммуносупрессии после трансплантации печени детям раннего возраста
US9528998B2 (en) 2010-04-16 2016-12-27 Abbott Laboratories Methods and reagents for diagnosing rheumatoid arthrtis
JP2016222656A (ja) * 2015-05-26 2016-12-28 学校法人東京薬科大学 炎症性腸疾患を抑制する抗体および該抗体を含む医薬組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
WO2012032511A2 (en) * 2010-09-07 2012-03-15 Stephen G Marx Kit for monitoring, detecting and staging gvhd
GB201021149D0 (en) * 2010-12-14 2011-01-26 Georg August Uni Gottingen Stiftung Offentlichen Rechts Use of a skin explant assay for mRNA expression analysis for the identification of new genes and drug targets associated with graft versus host disease
CN102550486B (zh) * 2012-01-10 2013-07-10 浙江大学 一种nod/scid小鼠异种移植物抗宿主病模型的建立方法
EP3173788A3 (en) * 2012-03-14 2017-07-12 Marx, Stephen Means and methods for diagnostics and therapeutics of diseases
WO2013168876A1 (ko) 2012-05-11 2013-11-14 가톨릭대학교 산학협력단 이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법
CA2995582A1 (en) 2015-08-19 2017-02-23 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
CN115327118A (zh) * 2022-09-05 2022-11-11 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Cd38+hla-dr+cd8+t细胞在gvhd早期诊断中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521927A (ja) * 2000-02-03 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
JP2007051980A (ja) 2005-08-19 2007-03-01 Okayama Univ 移植片対宿主病の検査方法、検査用試薬ならびに予防薬および／または治療薬のスクリーニング方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351427B2 (en) 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
ITMI991299A1 (it) * 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
AU2002219828A1 (en) * 2000-11-14 2002-05-27 The General Hospital Corporation Blockade of T cell migration into epithelial GVHD target tissues
US7304040B2 (en) * 2001-11-02 2007-12-04 Kensuke Egashira Suppression of post-transplant arteriosclerosis
DK1461300T3 (da) * 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
WO2004050836A2 (en) * 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
EP1671648A4 (en) 2003-10-02 2009-07-08 Eisai R&D Man Co Ltd PREVENTION AND TREATMENT OF GVHD
RU2251974C1 (ru) * 2003-10-30 2005-05-20 Московский научно-исследовательский онкологический институт им. П.А. Герцена МЗ России Способ диагностики жизнеспособности костного трансплантата при реконструктивно-пластических операциях
US20060105367A1 (en) 2004-10-14 2006-05-18 Harald Mischak Method and markers for the diagnosis of Graft versus Host Disease (GvHD)
GB0427827D0 (en) * 2004-12-20 2005-01-19 Randox Lab Ltd Method of diagnosis
EP2520588A1 (en) * 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521927A (ja) * 2000-02-03 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
JP2007051980A (ja) 2005-08-19 2007-03-01 Okayama Univ 移植片対宿主病の検査方法、検査用試薬ならびに予防薬および／または治療薬のスクリーニング方法

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ABDI REZA ET AL.: "Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo", JOURNAL OF IMMUNOLOGY, vol. 172, no. 2, 2004, pages 767 - 775, XP008128051 *
FERRARA JL; REDDY P: "Pathophysiology of graft-versus-host disease", SEMIN HEMATOL., vol. 43, 2006, pages 3 - 10
HORI TSUKASA ET AL.: "CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease", BLOOD, vol. 111, no. 8, 15 April 2008 (2008-04-15), pages 4403 - 4412, XP002586771 *
KAISER T; KAMAL H; RANK A ET AL.: "Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation", BLOOD, vol. 104, 2004, pages 340 - 349
MASAYOSHI M. ET AL.: "Non-invasive diagnosis of acute rejection by measuring chemokinegene expression in urine of kidney transplant recipients", JOURNAL OF UROLOGY, vol. 171, no. 4, SUPPL., 2004, pages 490, XP008128136 *
MURAI M. ET AL.: "Kyusei GVHD ni yoru Kan Shinjun CD8 Saibo ni Okeru Chemokine no Kan'yo", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 28, 1998, pages 152 + ABSTR. NO. 3-A4-111 *
NOMURA SHOSAKU ET AL.: "Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation", TRANSPLANT. IMMUNOLOGY, vol. 15, no. 4, 2006, pages 247 - 253, XP025013517 *
PANOSKALTSIS-MORTARI A. ET AL.: "Amelioration of idiopathic pneumonia syndrome (IPS) and GVHD by KGF-pretreatment is partly mediated via a STAT-6-dependent pathway in the host", BLOOD, vol. 108, no. 11, PART 1, 2006, pages 910A, XP008128134 *
PETRICOIN EF; ARDEKANI AM; HITT BA ET AL.: "Use of proteomic patterns in serum to identify ovarian cancer", LANCET, vol. 359, 2002, pages 572 - 577
REDDY P.: "Pathophysiology of acute graft-versus-host disease", HEMATOL ONCOL., vol. 21, 2003, pages 149 - 161
See also references of EP2163896A4 *
SUGERMAN P. ET AL.: "Kinetics of gene expression in murine cutaneous graft-versus-host disease", AM.J.PATH., June 2004 (2004-06-01)
SULLIVAN KM.: "Hematopoietic Cell Transplantation", 2004, BLACKWELL PUBLISHING, article "Graft vs. host disease", pages: 635 - 664
SULLIVAN KM: "Hematopoietic Cell Transplantation", 2004, BLACKWELL PUBLISHING, pages: 635 - 664
WYSOCKI CA; PANOSKALTSIS-MORTARI A; BLAZAR BR; SERODY JS: "Leukocyte migration and graft-versus-host disease", BLOOD, vol. 105, 2005, pages 4191 - 4199
ZIEGLER J.A. ET AL.: "Chemokine profiling in patients with graft versus host disease (GVHD) following allogeneic blood stem cell transplantation", BLOOD, vol. 108, no. 11, PART 1, 2006, pages 814A - 815A, XP008128135 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011024458A1 (ja) * 2009-08-26 2011-03-03 北海道公立大学法人 札幌医科大学 宿主対移植片疾患の検査方法
US9528998B2 (en) 2010-04-16 2016-12-27 Abbott Laboratories Methods and reagents for diagnosing rheumatoid arthrtis
JP2016501526A (ja) * 2012-12-06 2016-01-21 エンリヴェックス セラピューティクス リミテッド 治療用アポトーシス細胞調製物、その製造方法及びその使用
JP2019047813A (ja) * 2012-12-06 2019-03-28 エンリヴェックス セラピューティクス リミテッド 治療用アポトーシス細胞調製物、その製造方法及びその使用
JP2016222656A (ja) * 2015-05-26 2016-12-28 学校法人東京薬科大学 炎症性腸疾患を抑制する抗体および該抗体を含む医薬組成物
RU2603461C1 (ru) * 2015-11-27 2016-11-27 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ подбора режима иммуносупрессии после трансплантации печени детям раннего возраста

Also Published As

Publication number Publication date
CA2692332A1 (en) 2008-12-31
US20100183586A1 (en) 2010-07-22
US20130065779A1 (en) 2013-03-14
RU2632434C2 (ru) 2017-10-04
RU2479846C2 (ru) 2013-04-20
JP5403752B2 (ja) 2014-01-29
CA2692332C (en) 2019-09-24
US20130267430A2 (en) 2013-10-10
US9631014B2 (en) 2017-04-25
CN101743473A (zh) 2010-06-16
CN101743473B (zh) 2014-03-19
EP2163896A4 (en) 2010-08-04
RU2012157473A (ru) 2014-07-10
EP2163896B1 (en) 2013-09-25
AU2008268842A1 (en) 2008-12-31
KR20100055390A (ko) 2010-05-26
JPWO2009001545A1 (ja) 2010-08-26
US20140234335A1 (en) 2014-08-21
RU2010101909A (ru) 2011-07-27
EP2163896A1 (en) 2010-03-17
KR101432191B1 (ko) 2014-08-20

Similar Documents

Publication Publication Date Title
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
WO2007092627A3 (en) Detection of cancer by elevated levels of bcl-2
WO2009092386A8 (en) A new method to measure and characterize microvesicles in the human body fluids
WO2000040749A3 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
WO2007137285A3 (en) Fluid access interface
WO2014066913A8 (en) Health diagnostic systems and methods
IN2014MN02060A (ja)
SG179122A1 (en) Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
WO2007090126A3 (en) Compositions and methods for detecting and quantifying toxic substances in disease states
WO2012047899A3 (en) Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
WO2008021290A8 (en) Organ-specific proteins and methods of their use
WO2009152607A8 (en) Methods and kits for diagnosing neurodegenerative disease
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
WO2010136163A8 (en) Secernin-1 as a marker for cancer
WO2012103324A3 (en) Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
EP2573192A4 (en) METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
WO2009014342A3 (en) Markers and kit for diagnosis of alzheimer's disease
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
WO2013101276A3 (en) Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
WO2012167887A8 (en) Diagnostic use of prosomatostatin
EP1898215A4 (en) METHOD FOR ANALYZING ENDOCRINE SUBSTANCE IN A SPECIMEN

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021422.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764208

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520345

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008268842

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692332

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008268842

Country of ref document: AU

Date of ref document: 20080623

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008764208

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107001343

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 392/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010101909

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12666209

Country of ref document: US